SAN DIEGO, CA--(Marketwire - May 08, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that J. Christopher Mizer has joined the Company as President and Chief Operating Officer of its Regen BioPharma subsidiary. Regen BioPharma is a "superincubator" focused on accelerated development of undervalued intellectual property in the area of stem cells therapies. Mr. Mizer will spearhead license negotiations, development of academic and corporate partnerships, creation of business units, and value optimization of technologies that are being advanced by Regen BioPharma.
David Koos, Chairman & CEO of Bio-Matrix Scientific Group, stated, "We are building a world-class team in the field of translational, regenerative medicine. Mr. Mizer's solid track record of building companies, attracting funding, attaining profitability, and enabling successful exist strategies uniquely positions him to lead the operational aspects of our novel stem cell company."
Mr. Mizer is the founder of Vivaris, Ltd., a private investment partnership focused on life science and healthcare opportunities, and co-founder of ChinaBio Capital Partners. He was formerly an investment banker with Key Capital Markets and a consultant with Ernst and Young. He holds a Master of Science degree in biology and an M.B.A. from Case Western Reserve University.
About Bio-Matrix Scientific Group, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.
Areas of interest to the Company include:
- Chronic Obstructive Pulmonary Disease (COPD)
- Heart Related illness
- Circulatory issues
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.